Moody Aldrich Partners LLC Buys New Shares in Replimune Group, Inc. (NASDAQ:REPL)
Moody Aldrich Partners LLC bought a new stake in Replimune Group, Inc. (NASDAQ:REPL – Get Rating) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 91,437 shares of the company’s stock, valued at approximately $2,487,000. Moody Aldrich Partners LLC owned approximately 0.18% of Replimune Group at the end of the most recent quarter.
→ Urgent Warning (From Weiss Ratings)
Several other hedge funds and other institutional investors have also made changes to their positions in REPL. BlackRock Inc. lifted its holdings in shares of Replimune Group by 19.0% during the third quarter. BlackRock Inc. now owns 2,766,371 shares of the company’s stock worth $47,775,000 after buying an additional 442,331 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Replimune Group by 5.1% during the third quarter. Vanguard Group Inc. now owns 1,848,167 shares of the company’s stock worth $31,919,000 after purchasing an additional 89,618 shares during the last quarter. State Street Corp boosted its holdings in Replimune Group by 36.6% in the first quarter. State Street Corp now owns 1,712,037 shares of the company’s stock valued at $29,070,000 after acquiring an additional 458,420 shares during the last quarter. Emerald Advisers LLC boosted its holdings in Replimune Group by 4.0% in the third quarter. Emerald Advisers LLC now owns 1,136,586 shares of the company’s stock valued at $19,629,000 after acquiring an additional 43,263 shares during the last quarter. Finally, FMR LLC lifted its stake in Replimune Group by 0.9% in the second quarter. FMR LLC now owns 1,090,210 shares of the company’s stock valued at $19,057,000 after buying an additional 9,380 shares during the period. 87.83% of the stock is owned by institutional investors.
Replimune Group Stock Up 0.4 %
Shares of NASDAQ REPL traded up $0.07 during mid-day trading on Friday, hitting $17.55. 308,175 shares of the stock traded hands, compared to its average volume of 590,219. The company has a debt-to-equity ratio of 0.09, a quick ratio of 23.58 and a current ratio of 23.58. Replimune Group, Inc. has a 52 week low of $13.05 and a 52 week high of $29.52. The company has a market cap of $994.21 million, a price-to-earnings ratio of -6.11 and a beta of 1.69. The stock has a fifty day moving average price of $23.22 and a 200-day moving average price of $21.83.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the company. SVB Leerink increased their price target on Replimune Group from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Wednesday, December 7th. Piper Sandler increased their price target on Replimune Group from $43.00 to $58.00 in a research note on Wednesday, December 14th. EF Hutton Acquisition Co. I assumed coverage on Replimune Group in a report on Thursday, January 5th. They set a “buy” rating and a $60.00 price objective on the stock. BMO Capital Markets raised their price target on Replimune Group from $40.00 to $70.00 and gave the company an “outperform” rating in a report on Monday, December 12th. Finally, HC Wainwright raised their price objective on Replimune Group from $48.00 to $50.00 and gave the company a “buy” rating in a report on Friday, February 10th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Replimune Group presently has an average rating of “Buy” and a consensus target price of $51.86.
About Replimune Group
Replimune Group, Inc is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm’s Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Replimune Group, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Replimune Group wasn’t on the list.
While Replimune Group currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Elon Musk’s Next Move
Wondering when you’ll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
